Prevalence of IgG and IgM to SARS-CoV-2 and other human coronaviruses in Sierra Leone, Democratic Republic of Congo, and Uganda: A Longitudinal Study

Supplementary information

Table of Contents

Suppl. Table 1. Serological profiles of unvaccinated participants over time2
Suppl. Figure 1. Reverse Cumulative distribution curves – MFI of IgG to SARS-CoV-2 receptor binding domain (RBD) and nucleocapsid protein (NP) – among unvaccinated3
Suppl. Figure 2. Correlation between MERS NP and other HCoVs at baseline. Line: line of best fit
Suppl. Table 2. Correlation coefficients of MFI units of IgG to MERS-NP and HCoVs among all samples, and MERS-NP with SARS2 among the unvaccinated
Suppl. Table 3. Correlation coefficients of MFI units to SARS-CoV-2 NP / RBD protein and HCoVs, among the unvaccinated, at the time of enrolment
Suppl. Table 4. A sensitivity analysis to assess if SARS-CoV-2 seroprevalence (RBD/NP IgG/M) differs in samples with evidence of high MFI to other HCoVs ¹
Suppl. Table 5. Factors associated with remaining persistently negative throughout follow up in the DRC
Suppl. Figure. 4. HCoV IgG MFI units at baseline, comparing those who were seropositive to SARS-CoV-2 at least once during the study ('0' below, n=163) with those remained persistently seronegative to SARS-CoV-2 IgG/M to RBD/ N ('1' below, n=23), in Goma17
Suppl. Figure 5. Trends in IgG MFI to SARS-COV-2 RBD by time since vaccination in Sierra Leone and Uganda
Suppl. Table 7: Analyses and sample sizes

Luminex IgG/IgM RBD/NP profile	M0	M2	M4	DRC (N=1	86)	SL (N=6	52)	UG (N=9	98)
				n	%	n	%	n	%
1 – Persistently positive	positive	positive	positive	119	64.0	41	66.1	83	84.7
2 - Seroreversion	positive	positive	negative	5	2.7	8	12.9	2	2.0
3 - Seroreversion	positive	negative	negative	2	1.1	1	1.6	1	1.0
$4 - Reinfection^1$	positive	negative	positive	8	4.3	6	9.7	4	4.1
5 – Persistently negative	negative	negative	negative	23	12.4	0	0	4	4.1
6 - Acquisition	negative	negative	positive	4	2.2	0	0	3	3.1
7 - Acquisition	negative	positive	positive	24	12.9	4	6.5	1	1.0
8 – Acquisition ¹	negative	positive	negative	1	0.0	2	3.2	0	0.0

Suppl. Table 1. Serological profiles of unvaccinated participants over time

¹This could also represent misclassification of the M2 sample. Participants included in this table had to have available IgG and IgM data for RBD and NP for every timepoint and had to remain unvaccinated for the duration of the study.

Suppl. Figure 1. Reverse Cumulative distribution curves – MFI of IgG to SARS-CoV-2 receptor binding domain (RBD) and nucleocapsid protein (NP) – among unvaccinated

i. DRC



ii. Sierra Leone





Suppl. Figure 2. Correlation between MERS NP and other HCoVs at baseline. Line: line of best fit



a) DRC *excluding 1 value of MERS NP MFI > 10,000







c) Uganda



Antigen	Corr coef. IgG to MERS NP	p-value	n
	MFI		
DRC			
SARS-CoV-2 NP	0.093	0.1959	195
OC43 NP	<mark>0.148</mark>	<mark>0.0389</mark>	195
HKU1 NP	0.048	0.5088	195
X229E NP	0 <mark>.158</mark>	<mark>0.0275</mark>	195
NL63 RBD	0.089	0.2161	195
Sierra Leone			
SARS-CoV-2 NP	0.098	0.2751	126
OC43 NP	-0.033	0.7122	126
HKU1 NP	0.0931	0.3	126
X229E NP	-0.016	0.8589	126
NL63 RBD	-0.106	0.239	126
Uganda			
SARS-CoV-2 NP	-0.046	0.503	213
OC43 NP	<mark>0.239</mark>	<mark>0.001</mark>	248
HKU1 NP	<mark>0.2141</mark>	<mark>0.0007</mark>	248
X229E	0.107	0.0944	248
NL63 RBD	<mark>0.1720</mark>	<mark>0.007</mark>	248

Suppl. Table 2. Correlation coefficients of MFI units of IgG to MERS-NP and HCoVs among all samples, and MERS-NP with SARS2 among the unvaccinated



Suppl. Figure 3. Correlations between MFI of IgG to SARS-CoV-2 NP/RBD and MFI of IgG to HCoVs among the unvaccinated at enrolment





Antigen	HCoV 'seroprevalence' D0 among unvaccinated	Corr coef. IgG to SARS- COV-2 NP MFI	p-value	n
DRC				
OC43-NP	2.6	0.1513	<mark>0.0342</mark>	196
X229E- NP	2.6	0.4608	<mark><0.001</mark>	196
HKU1- NP	11.2	0.1024	0.1534	196
NL63 - S1*	4.6	0.2120	<mark>0.0029</mark>	196
MERS-NP	7.14	0.093	0.1959	196
Sierra Leone				
OC43-NP	19.1	0.0426	0.6358	126
X229E- NP	3.2	0.1654	0.0642	126
HKU1- NP	23.0	-0.127	0.1558	126
NL63-S1*	7.9	0.0214	0.8120	126
MERS-NP	36.5	0.098	0.2751	126
Uganda				
OC43-NP	4.7	-0.039	0.5699	213
X229E- NP	7.5	0.3551	<mark><0.001</mark>	213
HKU1- NP	12.7	0.0434	0.5285	213
NL63 - S1*	13.2	0.0419	0.5431	213
MERS-NP	14.6	-0.0481	0.4850	213

Suppl. Table 3. Correlation coefficients of MFI units to SARS-CoV-2 NP / RBD protein and HCoVs, among the unvaccinated, at the time of enrolment

*corr coef is against SARS-CoV-2 RBD domain as the NL63 antigen was the S1 protein

Suppl. Table 4. A sensitivity analysis to assess if SARS-CoV-2 seroprevalence (RBD/NP IgG/M) differs in samples with evidence of high MFI to other $\rm HCoVs^1$

¹ In the table we defined the HCoV 'seropositive' column as those with IgG MFI units 3 standard deviations above the mean of European negative controls. The data on other HCoVs are based on IgG to OC43 NP, HKU1 NP, 229E NP, NL63 S1 protein

a) DRC

		OC43 NP IgG			Seroprevalence to OC43	Chi2 p-value
		(-)	(+)	Total		
SARS2	(-)	56	2	58	3.4%	
RBD/NP IgG /	(+)	135	3	138	2.2%	
Igivi	Total	191	5	196	2.6%	0.606
	Seroprevalence to SARS2	71%	60%			

		HKU1 NP IgG	ł	Seroprevalence to HKU1	Chi2 p-value	
		(-)	(+)	Total		
SARS2	(-)	51	7	58	12.1%	
RBD/NP IgG /	(+)	123	15	138	10.9%	
Igivi	Total	174	22	196	11.2%	
	seroprevalence to					0.808
	SARS2	71%	68%			

		229E NP IgG				
					Seroprevalence	Chi2 n-value
				Tetel	10 22712	CIII2 p-value
		(-)	(+)	Total		
Luminex	(-)	57	1	58	1.7%	
RBD/NP IgG /	(+)	134	4	138	2.9%	
Igivi	Total	191	5	196	2.6%	
	seroprevalence to					0.634
	SARS2	70%	80%			

		NL63 S1 IgG				
					Seroprevalence to NL63	Chi2 p-value
		(-)	(+)	Total		
Luminex	(-)	55	3	58	5.2%	
RBD/NP IgG /	(+)	132	6	138	4.3%	
Igivi	Total	187	9	196	4.6%	
	seroprevalence to SARS2	71%	67%			0.801

b) Sierra Leone

OC43 NP IgG			Seroprevalence to OC43	Chi2 p-value		
		(-)	(+)	Total		
SARS2	(-)	10	4	14	28.6%	
RBD/NP IgG / IgM	(+)	92	20	112	17.9%	
IgO / IgW	Total	102	24	126	19.0%	
	Seroprevalence to SARS2	90%	83%			0.336

		HKU1 NP IgG	ſ	Seroprevalence to HKU1	Chi2 p-value	
		(-)	(+)	Total		
SARS2	(-)	10	4	14	28.6%	
RBD/NP JaG / JaM	(+)	87	25	112	22.3%	
igo / igivi	Total	97	29	126	23.0%	
	Seroprevalence to SARS2	90%	86%			0.600

		229E NP IgG			Seroprevalence to 229E	Chi2 n-value
						Cili2 p value
		(-)	(+)	Total		
SARS2	(-)	13	1	14	7.1%	
RBD/NP JaG / JaM	(+)	109	3	112	2.7%	
	Total	122	4	126	3.2%	
	Seroprevalence to					0.369
	SARS2	89%	75%			

		NL63 S1 IgG		Seroprevalence to NL63	Chi2 p-value	
		(-)	(+)	Total		
SARS2	(-)	14	0	14	0.0%	
RBD/NP JaG / JaM	(+)	102	10	112	8.9%	
1507 1511	Total	116	10	126	7.9%	
	Seroprevalence to SARS2	88%	100%			0.244

c) Uganda among unvaccinated at baseline only

		Seroprevalence	Chi2 p-			
				to OC43	value	
		(-)	(+)	Total		
SARS2	(-)	21	2	23	8.7%	
RBD/NP IgG / IgM	(+)	182	8	190	4.2%	
	Total	203	10	213	4.7%	
	seroprevalence to	000/	800/			0.9224

		HKU1 NP IgG		Seroprevalence to HKU1	Chi2 p- value	
		(-)	(+)	Total		
SARS2 RBD/NP IgG / IgM	(-)	20	3	23	13.0%	
	(+)	166	24	190	12.6%	
	Total	186	27	213	12.7%	
	seroprevalence to SARS2	89%	89%			0.003

		229E NP IgG				
				Seroprevalence to HKU1	Chi2 p-value	
		(-)	(+)	Total		
SARS2	(-)	22	1	23	4.4%	
RBD/NP IgG / IgM	(+)	175	15	190	7.9%	
	Total	197	16	213	7.5%	
	seroprevalence to					0.372
	SARS2	89%	94%			

		NL63 S1 IgG		Seroprevalence to NL63	Chi2 p- value	
		(-)	(+)	Total		
SARS2 RBD/NP IgG / IgM	(-)	20	3	23	13.0%	
	(+)	165	25	190	13.2%	
	Total	185	28	213	13.2%	
	seroprevalence to SARS2	89%	89%			0.0002

DRC	Cont	ntrol Persistently negative		Total	OR	95%CI	LRT p- value	
	Ν	% (col)	N	% (col)			
All	163	87.6	23	12.4	186			
Age group								
<30 yrs	41	25.2	7	30.4	48	1		0.848
30-45 yrs	72	44.2	9	39.1	81	0.73	0.25-2.11	
>45yrs	50	30.7	7	30.4	57	0.82	0.27-2.53	
Sex								
Male	62	38.0	18	78.3	80	5.87	2.07-16.6	< 0.001
Female	101	62.0	5	21.7	106	1		
Role ²								
Doctor, CO, nurse	135	82.8	19	82.6	154	1		0.980
Support staff ⁴	28	17.2	4	17.4	32	1.01	0.57-1.79	
Highest level of schooling								
None ⁷						~		
Complete primary	1	0.6	0	0	1	~		~
Incomplete secondary	12	7.4	2	8.7	14	1.18	0.25-5.66	
Complete secondary & above	149	92.0	21	91.3	170	1		
Smoke once/ week or more								
No	162	99.4	23	100	185	~		
Yes	0	0	0	0	0	~		
MUAC								
Underweight (<24cm)	13	8.0	4	17.4	17	2.19	0.64-7.55	0.287
Normal	114	69.9	16	69.6	130	1		
Obese (>31cm)	36	22.1	3	13.0	39	0.59	0.16-2.15	
Known contact with a confirmed								
COVID-19 case								
Yes	42	25.8	5	21.7	47	1		0.673
No	121	74.2	18	78.3	139	1.25	0.44-3.57	
Use of a mask at work								
None of the time			_					
Half the time	27	16.6	5	21.7	32	1.38	0.44-4.33	0.834
Most but not all the time	82	50.3	11	47.8	93	1		
All the time	54	33.1	7	30.4	61	0.97	0.35-2.65	
Known Pre-existing conditions								
Yes	29	17.8	6	26.1	35	1.63	0.59-4.49	0.36
No	134	82.2	17	73.9	151	1		
COVID-19 vaccination								
Yes	0	0	0	0	0			
No	163	100	23	100	186			

Suppl. Table 5. Factors associated with remaining persistently negative throughout follow up in the DRC

Suppl. Figure. 4. HCoV IgG MFI units at baseline, comparing those who were seropositive to SARS-CoV-2 at least once during the study ('0' below, n=163) with those remained persistently seronegative to SARS-CoV-2 IgG/M to RBD/ N ('1' below, n=23), in Goma. P-values are for a Wilcoxon rank-sum test

Among those vaccinated before D0									
Masaka, Uganda	D0			M2			M4		
	N (Total)	n (pos)	%	N (Total)	n (pos)	%	N (Total)	n (pos)	%
SARS2 RBD IgG	35	30	85.7	35	32	91.4	34	32	94.1
SARS2 NP IgG	35	23	65.7	35	22	62.9	34	23	67.6
SARS2 RBD/NP IgG	35	31	88.6	35	33	94.3	34	32	94.1
SARS2 RBD/NP IgG/IgM	35	33	94.3	35	33	94.3	34	34	100.0
	Among those vaccinated between M0 and M2					Among those vaccinated between M2 and M4			
Masaka, Uganda	M2			M4			M4		
	N (Total)	n (pos)	%	N (Total)	n (pos)	%	N (Total)	n (pos)	%
SARS2 RBD IgG	54	47	87.0	51	46	90.2	41	33	80.5
SARS2 NP IgG	54	36	66.7	51	33	64.7	41	28	68.3
SARS2 RBD/NP IgG	54	49	90.7	51	48	94.1	41	33	80.5
SARS2 RBD/NP IgG/IgM	54	49	90.7	51	50	98.0	41	36	87.8
Kambia, Sierra Leone	Among t M2 N (Total)	hose vac n	ccinated	d between M4 N (Total)	M0 and	1 M2	Among the between M M4	ose vaccina 2 and M4	ited
	(10(a))	(pos)	% 0 7	(10(a))	(pos)	%	N (10tal)	n (pos)	<u>%0</u>
SAKS2 KBD IgG	40	34	85	40	24	60	12	-	58.3
SARS2NP IgG	40	27	67.5	40	29	72.5	12	5	41.7
SARS2 RBD/NP IgG SARS2 RBD/NP	40	35	87.5	40	32	80	12	8	66.7
IgG/IgM	40	37	92.5	40	33	82.5	12	8	66.7

Suppl. Table 6. Seroprevalence of SARS-CoV-2 in vaccinated 1

¹In DRC: all participants remained unvaccinated for the duration of the study. The tables are based on timing of first dose, some of these participants may have been given a second dose between month 2 and month 4

Suppl. Figure 5. Trends in IgG MFI to SARS-COV-2 RBD by time since vaccination in Sierra Leone and Uganda. Curves are estimated using LOWESS, locally weighted smoothing of scatterplot data. Dashed line is the cut off for seropositivity in each setting.

¹ In Sierra Leone, all participants had written records of vaccination and product: AstraZeneca dose 1 recipients n=45; Sinopharm dose 1 recipients n=33. Due to small numbers AstraZeneca and Sinopharm recipients were combined for the dose 2 analysis n=33.

² In Uganda 128 participants submitted data on the date of dose 1. Only 14 participants had a written record with product recorded in Uganda, and some of these dates could be mis-remembered as based on recall. A total of 91 participants submitted data on the date of dose 2. Four dates were excluded as outliers when we estimated the trend using LOWESS.

Suppl. Table 7: Analyses and sample sizes

	Research questions	Sample size			
					Refer to table/
		DRC	SL	UG	figure
1	Among unvaccinated: Prevalence of IgG/IgM to SARS2 as indicator of natural exposure (extent of transmission)	V1=196 V2=189 V2=189	V1=126 V2=75 V3=62	V1=213 V2=141 V3=98	Table 2
2	Among unvaccinated: Rate of waning of IgG after natural infection? Restricted to those persistently positive over time to attempt to restrict to a group with similar time of infection	n-119	n-41	n-83	Table 3 Fig 2
3	Among vaccinated: seroprevalence over time among those vaccinated before baseline (group 1), vaccinated between V1-V2 (group 2) and vaccinated between V2 and V3 (group 3)	0	Group1=35 group2=54 group3=41	Group 1=0 Group 2=40 Group 3= 12	Table 4
4	Among vaccinated: MFI units by time since vaccination (waning?) and prevalence of hybrid immunity	0	78	128	Supplementary information
5	Among vaccinated: does evidence of prior natural exposure affect vaccine responses?	0	seronegative at baseline=4 vs. seropositive at baseline=44	seronegative at baseline=12 vs seropositive at baseline=96	Figure 3
6	Among unvaccinated: Do responses to HCoVs correlate with SARS2 and do they interfere with seroprevalence estimates?	V1=196 V2=189 V2=189	V1=126 V2=75 V3=62	V1=213 V2=141 V3=98	Supplementary information
7	Among unvaccinated: Does IgG to HCoVs influence subsequent risk of acquisition (among those with no evidence of prior infection)	Remained uninfected=23 vs infected during follow up=28	0	0	Figure 1